Are Metabolically Normal but Obese Individuals at Lower Risk for All-Cause Mortality? by Kuk, Jennifer L. & Ardern, Chris I.
Are Metabolically Normal but Obese
Individuals at Lower Risk for All-Cause
Mortality?
JENNIFER L. KUK, PHD
CHRIS I. ARDERN, PHD
OBJECTIVE — The clinical relevance of the metabolically normal but obese phenotype for
mortality risk is unclear. This study examines the risk for all-cause mortality in metabolically
normal and abnormal obese (MNOB and MAOB, respectively) individuals.
RESEARCH DESIGN AND METHODS — The sample included 6,011 men and women
from the Third National Health and Nutrition Examination Survey (NHANES III) with public-access
mortality data linkage (follow-up 8.7 0.2 years; 292 deaths). Metabolically abnormal was deﬁned as
insulin resistance (IR) or two or more metabolic syndrome (MetSyn) criteria (excluding waist).
RESULTS — A total of 30% of obese subjects had IR, and 38.4% had two or more MetSyn factors,
whereas only 6.0% (or 1.6% of the whole population) were free from both IR and all MetSyn factors.
ByMetSynfactorsorIRalone,MNOBsubjects(hazardratio[HR]MetSyn2.80[1.18–6.65];HRIR2.58
[1.00–6.65]) and MAOB subjects (HRMetSyn 2.74 [1.46–5.15]; HRIR 3.09 [1.55–6.15]) had
similar elevations in mortality risk compared with metabolically normal, normal weight subjects.
CONCLUSIONS — Although a rare phenotype, obesity, even in the absence of overt meta-
bolic aberrations, is associated with increased all-cause mortality risk.
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R
ecentinteresthasfocusedonaunique
subgroup of obese individuals who
are “metabolically normal” (MNOB)
despite increased adiposity (1–4). The in-
terpretation of some of these studies is that
MNOB subjects are not at increased risk for
morbidity and mortality and that obesity
treatment is therefore unnecessary. This is
in clear contrast with the current U.S. obe-
sity treatment guidelines that suggest that
obeseindividualsshouldbetreatedfortheir
obesity, regardless of their cardiovascular
(CVD) risk status (5).
The purpose of this study is to exam-
ine all-cause mortality risk in “metaboli-
cally normal obese” and “metabolically
abnormal obese” (MAOB) phenotypes.
RESEARCH DESIGN AND
METHODS— A sample of 6,011
adults (age 18–65 years) from the Third
NationalHealthandNutritionExamination
Survey(NHANESIII)PublicAccessMortal-
ityLinkagewasused.Age,sex,income,eth-
nicity, smoking status, exercise frequency,
dietary fat (30%), alcohol intake, inten-
tions to lose weight over the last year (yes/
no),andself-reportedbodyweight10years
prior were assessed by questionnaire. BMI
cutoffs for normal weight (18.5–25 kg/m
2),
overweight (25–29.9 kg/m
2), and obese
(30 kg/m
2) were used. To increase the
sample size (n  6,011 vs. 3,320), partici-
pants with fasting data (6 vs. 8 h) for at
least three of the four MetSyn criteria were
included.
Metabolicabnormalitiesweredeﬁned
as follows (6,7): 1) triglycerides 1.69
mmol/l or medications; 2) systolic blood
pressure 130 mmHg, diastolic blood
pressure 85 mmHg, or medications; 3)
glucose 5.6 mmol/l or medications; 4)
HDL cholesterol 1.04 mmol/l for men
and1.29mmol/lforwomen;and5)ho-
meostasis model assessment (HOMA)
2.5 (n  4,602).
Metabolically normal was deﬁned us-
ing three separate deﬁnitions: 1) insulin
sensitive by HOMA; 2) one or fewer
MetSyn criteria; or 3) absence of all
MetSyn criteria and IR.
Statistical analysis
Cox regression was used to assess risk for
all-cause mortality, adjusting for age, sex,
income,smokingstatus,ethnicity,andal-
cohol. Because of small cell sizes, mortal-
ity analyses were limited to metabolically
normaldeﬁnitions1and2.Analyseswere
performed using SAS version 9.1 or SUD-
DAN 10.0, weighted to be representative
of the U.S. population.
RESULTS— Within the sample, 25.6%
of participants were free from all MetSyn
factors and IR, wherein MNOB repre-
sented 1.3% of the population and 6.0%
oftheobese.Theproportionofobesewho
were MNOB by IR alone (30.2%) or had
1 MetSyn factor (38.4%) was consider-
ably higher than those with no MetSyn
factors (9.4%).
During the 8.7  0.2 year follow-up,
there were 292 (5%) deaths. As deﬁned
by MetSyn factors, MNOB (hazard ratio
[HR] 2.80 [1.18–6.65]) and MAOB (HR
2.74 [1.46–5.15]) were associated with
increased mortality risk compared with
MNNW (referent) (Figure 1). All IR BMI
categories and MNOB were associated
with increased mortality risk (MNOB:
HR 2.58 [1.00–6.65]; metabolically
abnormal normal weight: HR 2.26
[1.19–4.42]; metabolically abnormal
overweight: HR 2.44 [1.34–4.42];
MAOB: HR 3.09 [1.55–6.15]).
Regardless of deﬁnition, MAOB sub-
jects had a higher BMI and waist than
MNOB subjects (P  0.05) but reported
similar dietary fat, alcohol consumption,
andweightlossintentions(P0.10).Ex-
ercise frequency was signiﬁcantly lower
in IR obese but not by MetSyn factors.
MAOB subjects by MetSyn factors, but
not IR, were older (7.5 years) and heavier
(7.7 kg) 10 years ago.
CONCLUSIONS — This analysis
suggests that a truly metabolically normal
obese individual is a rare phenotype, ac-
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Moreover, obese individuals are at higher
risk of mortality than their nonobese
counterparts, regardless of whether they
present with insulin resistance or a clus-
tering of metabolic risk factors.
Previous studies report MNOB sub-
jects to be 11–40% of obese subjects
(1,3), whereas we report MNOB subjects
to be 6.0–38.4% of obese subjects de-
pending on the deﬁnition. We used a
more stringent deﬁnition with lower clin-
icalcutoffsandaHOMAcutoffof2.5that
is associated with clamp-measured IR (7)
asopposedtoanarbitrary90thpercentile
cutoff of 5.13. Despite our stricter deﬁni-
tion,thetrueprevalenceofMNOBmayin
fact be lower than the 6.0% that we re-
port, since individuals in negative energy
balance typically display metabolic pro-
ﬁlesthatarebetterthanexpectedfortheir
level of obesity (8). Because over two-
thirds of obese individuals are attempting
to lose weight (9), some MNOB subjects
may be in negative energy balance. Nev-
ertheless, reported intentions to lose
weightwerenotdifferentbetweenMNOB
and MAOB subjects.
The name “metabolically normal” im-
plies MNOB subjects are not at an ele-
vated health risk. For example, Brochu et
al. (1) identiﬁed a subgroup of MNOB
postmenopausal women who were insu-
lin sensitive and questioned the medical
urgencytotreatthesewomenastheywere
“metabolically normal.” The notion that
some obese individuals may not require
obesity treatment is in contrast to current
U.S. obesity treatment algorithms (5) that
recommend overweight individuals with
two or more CVD risk factors and all
obese individuals regardless of their risk
proﬁleshouldbetreated.Thealgorithmde-
ﬁnes CVD risk using nonmetabolic (age,
smoking,andpersonal/familyCVDhistory)
and metabolic (LDL, HDL, hypertension,
and glucose) factors. Although important,
manyofthenonmetabolicCVDfactorscan-
not be altered. Thus, examination of modi-
ﬁable metabolic factors may be more
clinically relevant and useful.
That MAOB subjects were older and
more obese currently and 10 years prior
may imply that MNOB subjects have not
had sufﬁciently high levels of obesity, or
adequate time for metabolic abnormali-
ties to develop as a consequence of their
obesity (10). Alternatively, increased
mortality risk could be mediated through
both metabolic and nonmetabolic conse-
quences. Obese individuals are more
likely to die from traumatic incidences
(11) and have cancer diagnosed at more
advanced stages than their normal weight
counterparts(12).Further,weightbiasby
some health professionals results in
greater reluctance to provide health
care—a problem that is compounded by
the fact that obese individuals are more
likely to avoid seeking health care (13).
RegardlessofthereasonswhyMNOBand
MAOB subjects are at similarly elevated
mortalityrisk,theseﬁndingsreinforcethe
importance of obesity reduction in all
obese individuals.
Insummary,obesityintheabsenceof
metabolic abnormalities is a rare condi-
tion.Further,obesityisassociatedwithan
increased risk for all-cause mortality, re-
gardless of whether the obese patients
present with insulin resistance or a clus-
tering of metabolic risk factors. As such,
weight management should continue to
be a target for reducing morbidity and
mortality in all obese individuals.
Acknowledgments— TheNHANESIIIstudy
with mortality follow-up was funded and con-
ducted, and the data were made publically
available, by the Centers for Disease Control
and Prevention.
No potential conﬂicts of interest relevant to
this article were reported.
The authors had full access to all of the data
in the study and take responsibility for the
integrity of the data and the accuracy of the
data analysis.
References
1. Brochu M, Tchernof A, Dionne IJ, Sites
CK, Eltabbakh GH, Sims EA, Poehlman
ET. What are the physical characteristics
associated with a normal metabolic pro-
ﬁle despite a high level of obesity in post-
menopausal women? J Clin Endocrinol
Metab 2001;86:1020–1025
2. SimsEA.Aretherepersonswhoareobese,
but metabolically healthy? Metabolism
2001;50:1499–1504
3. StefanN,KantartzisK,MachannJ,Schick
F, Thamer C, Rittig K, Balletshofer B,
Machicao F, Fritsche A, Haring H-U.
Identiﬁcation and characterization of
metabolically benign obesity in humans.
Arch Intern Med 2008;168:1609–1616
4. Wildman RP, Muntner P, Reynolds K,
McGinn AP, Rajpathak S, Wylie-Rosett J,
Sowers MR. The obese without cardiom-
etabolicriskfactorclusteringandthenor-
mal weight with cardiometabolic risk
factor clustering: prevalence and corre-
lates of 2 phenotypes among the US pop-
ulation (NHANES 1999–2004). Arch
Intern Med 2008;168:1617–1624
5. Clinical Guidelines on the Identiﬁcation,
Evaluation, and Treatment of Overweight
and Obesity in Adults: the Evidence Re-
port: National Institutes of Health. Obes
Res 1998;6 (Suppl. 2):51S–209S
6. Executive Summary of the Third Report of
the National Cholesterol Education Pro-
gram (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment
Panel III). JAMA 2001;285:2486–2497
7. Matthews DR, Hosker JP, Rudenski AS,
Naylor BA, Treacher DF, Turner RC. Ho-
Figure 1—Relative risk of all-cause mortality by BMI category and metabolic status as deﬁned by MetSyn factors (A) and insulin resistance (B)
criteria. *HR signiﬁcantly different from MNNW referent (P  0.05). Data are adjusted for age, sex, income, ethnicity, smoking status, and alcohol
consumption. Metabolically normal (MN) was deﬁned as one or less MetSyn risk factor or HOMA 2.5. MA, metabolically abnormal; NW, normal
weight; OB, obese; OW, overweight.
Metabolic proﬁle, obesity, and mortality risk
2298 DIABETES CARE, VOLUME 32, NUMBER 12, DECEMBER 2009 care.diabetesjournals.orgmeostasis model assessment: insulin resis-
tance and -cell function from fasting
plasma glucose and insulin concentrations
in man. Diabetologia 1985;28:412–419
8. Greco AV, Mingrone G, Giancaterini A,
Manco M, Morroni M, Cinti S, Granzotto
M, Vettor R, Camastra S, Ferrannini E.
Insulin resistance in morbid obesity: re-
versalwithintramyocellularfatdepletion.
Diabetes 2002;51:144–151
9. Galuska DA, Will JC, Serdula MK, Ford
ES. Are health care professionals advising
obese patients to lose weight? JAMA
1999;282:1576–1578
10. Janssen I, Katzmarzyk PT, Ross R. Dura-
tion of overweight and metabolic health
risk in American men and women. Ann
Epidemiol 2004;14:585–591
11. Viano DC, Parenteau CS, Edwards ML.
Crashinjuryrisksforobeseoccupantsus-
ingamatched-pairanalysis.TrafﬁcInjury
Prevention 2008;9:59–64
12. Hahn KME, Bondy ML, Selvan M, Lund
MJ, Liff JM, Flagg EW, Brinton LA, Por-
ter P, Eley JW, Coates RJ. Factors asso-
ciated with advanced disease stage at
diagnosis in a population-based study
of patients with newly diagnosed breast
cancer.AmJEpidemiol2007;166:1035-
1044
13. Puhl R, Brownell KD. Bias, discrimina-
tion, and obesity. Obesity 2001;9:788–
805
Kuk and Ardern
care.diabetesjournals.org DIABETES CARE, VOLUME 32, NUMBER 12, DECEMBER 2009 2299